TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE B-

NCT05425004: Cabozantinib for Patients With Recurrent or Progressive Meningioma

Sponsor: Baptist Health South Florida · Phase: PHASE2 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 24 pts

Competing Trials Overlap

4 Active Trials

Excess Burn Exposure

$730,400

Rescue Site Savings

+$498,000

Unlock Full NCT05425004 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT05425004 Rescue Dossier →